Q2 Earnings Estimate for CATX Issued By B. Riley

Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Equities research analysts at B. Riley issued their Q2 2025 earnings estimates for Perspective Therapeutics in a research note issued on Sunday, June 22nd. B. Riley analyst Y. Zhi forecasts that the company will earn ($0.30) per share for the quarter. B. Riley currently has a "Buy" rating and a $12.00 target price on the stock. The consensus estimate for Perspective Therapeutics' current full-year earnings is ($0.88) per share. B. Riley also issued estimates for Perspective Therapeutics' Q3 2025 earnings at ($0.30) EPS and Q4 2025 earnings at ($0.30) EPS.

Several other brokerages have also recently weighed in on CATX. Wedbush reiterated an "outperform" rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a research note on Monday. Lifesci Capital upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a research report on Thursday, March 6th. Royal Bank Of Canada upgraded Perspective Therapeutics from an "outperform" rating to a "moderate buy" rating and boosted their price target for the company from $15.00 to $16.00 in a research note on Tuesday, June 3rd. Truist Financial lowered their price objective on Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. Finally, HC Wainwright reiterated a "buy" rating and set a $10.00 target price on shares of Perspective Therapeutics in a research report on Monday, March 31st. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, Perspective Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $12.56.

Perspective Therapeutics Trading Down 0.3%

Shares of CATX stock traded down $0.01 on Tuesday, hitting $3.81. The company's stock had a trading volume of 1,381,845 shares, compared to its average volume of 1,094,579. The stock's 50 day moving average is $2.71 and its 200-day moving average is $2.84. Perspective Therapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $16.55.

Institutional Investors Weigh In On Perspective Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Deerfield Management Company L.P. Series C boosted its stake in shares of Perspective Therapeutics by 4.3% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 2,938,754 shares of the company's stock valued at $9,375,000 after purchasing an additional 120,991 shares in the last quarter. Octagon Capital Advisors LP raised its holdings in Perspective Therapeutics by 62.1% in the 4th quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company's stock valued at $7,352,000 after buying an additional 882,528 shares during the last quarter. Affinity Asset Advisors LLC boosted its position in Perspective Therapeutics by 71.1% during the 1st quarter. Affinity Asset Advisors LLC now owns 2,224,196 shares of the company's stock worth $4,738,000 after buying an additional 924,196 shares during the period. Millennium Management LLC bought a new stake in Perspective Therapeutics during the 4th quarter worth approximately $4,132,000. Finally, Nuveen LLC acquired a new position in Perspective Therapeutics in the 1st quarter valued at approximately $2,647,000. Institutional investors own 54.66% of the company's stock.

Insider Transactions at Perspective Therapeutics

In related news, Director Robert F. Williamson III acquired 38,145 shares of the company's stock in a transaction that occurred on Monday, March 31st. The stock was acquired at an average price of $2.14 per share, with a total value of $81,630.30. Following the purchase, the director now directly owns 108,982 shares in the company, valued at approximately $233,221.48. This trade represents a 53.85% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Juan Graham bought 33,333 shares of the business's stock in a transaction on Friday, March 28th. The stock was bought at an average price of $2.25 per share, for a total transaction of $74,999.25. Following the transaction, the chief financial officer now directly owns 35,354 shares of the company's stock, valued at approximately $79,546.50. This represents a 1,649.33% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 115,696 shares of company stock valued at $256,344. Corporate insiders own 3.72% of the company's stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.